- Home
- WATT vs ICU Comparison
WATT vs ICU Comparison
Compare WATT & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- ICU
- Stock Information
- Founded
- WATT 2012
- ICU 2018
- Country
- WATT United States
- ICU United States
- Employees
- WATT N/A
- ICU N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- WATT Technology
- ICU Health Care
- Exchange
- WATT Nasdaq
- ICU Nasdaq
- Market Cap
- WATT 9.1M
- ICU 10.4M
- IPO Year
- WATT 2014
- ICU N/A
- Fundamental
- Price
- WATT $0.42
- ICU $1.75
- Analyst Decision
- WATT Strong Buy
- ICU
- Analyst Count
- WATT 2
- ICU 0
- Target Price
- WATT $2.25
- ICU N/A
- AVG Volume (30 Days)
- WATT 929.8K
- ICU 24.8K
- Earning Date
- WATT 03-27-2025
- ICU 04-15-2025
- Dividend Yield
- WATT N/A
- ICU N/A
- EPS Growth
- WATT N/A
- ICU N/A
- EPS
- WATT N/A
- ICU N/A
- Revenue
- WATT $431,184.00
- ICU $68,000.00
- Revenue This Year
- WATT $95.75
- ICU N/A
- Revenue Next Year
- WATT $834.07
- ICU $358.72
- P/E Ratio
- WATT N/A
- ICU N/A
- Revenue Growth
- WATT N/A
- ICU N/A
- 52 Week Low
- WATT $0.28
- ICU $1.50
- 52 Week High
- WATT $2.70
- ICU $27.50
- Technical
- Relative Strength Index (RSI)
- WATT 44.73
- ICU 43.77
- Support Level
- WATT $0.42
- ICU $1.71
- Resistance Level
- WATT $0.49
- ICU $1.99
- Average True Range (ATR)
- WATT 0.04
- ICU 0.23
- MACD
- WATT 0.00
- ICU -0.00
- Stochastic Oscillator
- WATT 29.60
- ICU 2.94
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.